Convoy Therapeutics, Inc®., Engages U.S. Investment Bank Mavericks Capital

Share Article

Convoy Therapeutics, Inc®., a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated through the use of a proprietary SPACE™ Technology Platform, announced today that it had engaged U.S. investment bank Mavericks Capital

News Image
We are delighted to be working with Mavericks Capital as we prepare for future growth and the next stage of clinical development of CycloPsorb™, our unique first-in-class, disease modifying topical treatment for psoriasis.

Convoy Therapeutics, Inc®., a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated through the use of a proprietary SPACE™ Technology Platform, announced today that it had engaged U.S. investment bank Mavericks Capital. Mavericks, headquartered in Silicon Valley, specializes in mergers & acquisitions, capital raising and strategic partnering for innovative, high growth, healthcare companies. Mavericks has been engaged as a strategic advisor and to assist Convoy with fundraising and partnership activities.

John Muraski, Ph.D., President and CEO, states "We are delighted to be working with Mavericks Capital as we prepare for future growth and the next stage of clinical development of CycloPsorb™, our unique first-in-class, disease modifying topical treatment for psoriasis. Mavericks has a world-class team with deep expertise in healthcare to deliver effective, content-driven investment banking services”.

Jeff Karan, Managing Partner, comments "Mavericks Capital is pleased to assist Convoy Therapeutics by providing sophisticated advisory services to capitalize on their unique platform and clinical pipeline. We are impressed with management's continued focus on core competencies, high growth potential, and dedication to improving patient outcomes”.

About Convoy Therapeutics
Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset being developed internally.

About Mavericks Capital
Mavericks Capital, and its licensed broker dealer affiliate, Mavericks Capital Securities, specializes in mergers & acquisitions, strategic partnering and capital raising across the healthcare sector. Mavericks approach is differentiated by a cross-functional team with deep scientific and medical knowledge, proprietary analytics and three decades of investment banking transactional experience in life sciences.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Debbie Rinaldi, Director Business Development

Ann Deren Lewis, VP Business Development
@convoytx
since: 06/2013
Follow >
Convoy Therapeutics

Visit website